DPP-4 inhibitors, by elevating both GLP-1 and GIP levels, have likewise demonstrated efficacy in alleviating oxidative stress and neuroinflammation in AD and traumatic brain injury models [70–72]. This evidence concerns the gene GLP1R and Alzheimer disease.